Given that the activation of NF-κB can drive STING-dependent tumorigenic responses while inhibiting a Type I-IFN anti-cancer response, it is critical to understand how STING agonists not only impact STING signalling but also RECON signalling, which unfortunately is overlooked in virtually all studies on STING agonists. This evidence concerns the gene RECQL and cancer.